News & Updates

Individuals with atrial high-rates episodes (AHREs) are at greater risk of progression to atrial fibrillation (AF). But the good news is that treatment with antiarrhythmic medication appears to have a protective effect both on AHRE burden and AF risk.

The oral, small molecule Wee1 kinase inhibitor adavosertib exerts antitumour effects in patients with advanced recurrent or persistent uterine serous carcinoma, but this benefit appears to be limited by the drug’s tolerability, as shown in the single-arm, phase IIb ADAGIO study.

In the EPI-VITRAKVI study, the TRK* inhibitor larotrectinib reduces morbidity and the need for aggressive local therapies in children with infantile fibrosarcoma (IFS) compared with the current standard of care (SoC).

Among patients with enterobacterales bloodstream infection (BSI), switching from intravenous (IV) to oral antibiotics is noninferior to continuous IV antibiotic therapy in reducing treatment failure within 90 days, according to a study presented at ECCMID 2023.